CN103816281A - Traditional Chinese medicine composition for preventing and treating wind-heat common cold - Google Patents
Traditional Chinese medicine composition for preventing and treating wind-heat common cold Download PDFInfo
- Publication number
- CN103816281A CN103816281A CN201410082674.0A CN201410082674A CN103816281A CN 103816281 A CN103816281 A CN 103816281A CN 201410082674 A CN201410082674 A CN 201410082674A CN 103816281 A CN103816281 A CN 103816281A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- medicine
- volatile oil
- flos lonicerae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 201000009240 nasopharyngitis Diseases 0.000 title abstract 3
- 239000000341 volatile oil Substances 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims description 35
- 241000628997 Flos Species 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- 239000010231 banlangen Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 241000245240 Lonicera Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010011224 Cough Diseases 0.000 abstract description 22
- 208000002193 Pain Diseases 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 14
- 230000036407 pain Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 244000062189 Picria fel-terrae Species 0.000 abstract description 2
- 206010037660 Pyrexia Diseases 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 3
- 241000933211 Helicteres jamaicensis Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 27
- 241000700159 Rattus Species 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 239000003440 toxic substance Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000002510 pyrogen Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- -1 alpha-cyclodextrin Chemical class 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 210000003026 hypopharynx Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002151 Pleural effusion Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 231100000668 minimum lethal dose Toxicity 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 244000183233 Helicteres angustifolia Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241001276052 Merremia umbellata subsp. orientalis Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 description 1
- 229950006796 spiramycin ii Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for preventing and treating wind-heat common cold. The traditional Chinese medicine composition is prepared from the main raw materials of narrowleaf screwtree root and picria fel-terrae lour, other traditional Chinese medicines such as indigowoad root and honeysuckle can be added according to state of an illness, wherein the used honeysuckle refers to volatile oil extracted from the honeysuckle. A large number of experiments in vitro and animal experiments before clinical application, and clinical experiment prove that the traditional Chinese medicine composition provided by the invention has obvious effects on treating fever, cough, pain and the like, which are caused by wind-heat common cold.
Description
Technical field:
The invention belongs to the field of Chinese medicines, relate to the Chinese medicine composition of a kind of prevention and treatment anemopyretic cold.
Background technology:
Flu is the common exogenous diseases that being invaded by exogenous pathogen causes.Due to four o'clock six gas differences, and human quality's difference, wind and cold, wind heat and heat-damp in summer accompanied symptoms had therefore clinical.As anemopyretic cold, because wind heat is violated table, the heat stagnation flesh natural fibre line of meat, defends table discord, therefore see fever of the body, micro evil wind is cold, sweating is not smooth; Wind-heat troubling, distending pain in the head; Stifling the cleaning the street of heresy of wind heat, thus laryngopharynx swelling and pain, parched throat, thirst with desire to drink, turbid nasal discharge; Wind-heat invading the lung, impairment of purifying function of the lung, cough, expectoration sticky or Huang, tongue tip side of red, thin white fur of tongue or micro-Huang, floating and rapid pulse are that wind heat is invaded levying of defending in lung.This disease is attacked due to human body mainly due to wind-heat evil toxin, therefore its treatment is worked as take dispelling wind to relieve the exterior syndrome, heat-clearing and toxic substances removing as the rule for the treatment of.
Anemopyretic cold is the common high morbidity in the subtropical zones such as Guangxi.Although have the proved recipe much with better clinical effectiveness, as application number: CN200810073696.5) adopt " Folium Eucalypti Robustae and Flos Ilicis Asprellae " in prescription; In patent " a kind of Chinese medicinal tablet for the treatment of anemopyretic cold, upper respiratory tract infection or capsule and preparation method thereof, application number: CN201110456838.8 " prescription, adopt " Flos Ilicis Asprellae, Herba lygodii, Radix achyranthis asperae (Herba Achyranthis Asperae) and Merremia umbellata subsp. orientalis "; In patent " a kind of Chinese medicine preparation application number of Rhizoma Et Radix Baphicacanthis Cusiae: CN201310191571.3 " prescription, adopt " Rhizoma Et Radix Baphicacanthis Cusiae " etc.But have no the medicine that adopts Guangxi conventional crude drugs Radix Helicteris and Radix Picriae felterrae to carry out prescription and adopt modern technology of preparing to be prepared from.
Summary of the invention:
The Chinese medicine that the object of the present invention is to provide a kind of prevention and treatment anemopyretic cold, has dispelling wind to relieve the exterior syndrome, heat-clearing and toxic substances removing, dredging microcirculation, and cure rate is high.
Technical scheme of the present invention is such:
Treat a Chinese medicine composition for anemopyretic cold, the raw material of preparing described compositions comprises Radix Helicteris and Radix Picriae felterrae, and the amount ratio of the two is: 6～8 parts of Radix Helicteriss, and 5～7 parts of Radix Picriae felterrae, described part is weight portion.
The drug matching that can catch a cold with conventional treatment in above-mentioned composition, in optimization formula of the present invention, also comprises Radix Isatidis and/or Flos Lonicerae, the medicinal residues after volatile oil and extraction that Flos Lonicerae used refers to extract with Flos Lonicerae;
The preparation method of described Flos Lonicerae volatile oil and form can adopt this area routine techniques method, such as Flos Lonicerae is extracted after volatile oil, make according to a conventional method inclusion agent, then for the preparation of this pharmaceutical preparation.
The parts by weight proportioning of each raw material is: 6～8 parts of Radix Helicteriss, 5～7 parts of Radix Picriae felterrae, 5～7 parts and 5～7 portions Flos Loniceraes of Radix Isatidis.
In above-mentioned formula, can also add Radix Platycodonis and/or Radix Glycyrrhizae, consumption is 1.6～2.4 parts of Radix Platycodoniss, 1.6～2.4 parts, Radix Glycyrrhizae.
A kind of preferred parts by weight proportioning is: 2 parts, 7 parts of Radix Helicteriss, 7 parts of Radix Picriae felterrae, 6 parts of Flos Loniceraes, 6 parts of Radix Isatidis, 2 parts of Radix Platycodoniss and Radix Glycyrrhizae.
The monarch drug that plays main work in we is Radix Helicteris and Radix Picriae felterrae; Ministerial drug Flos Lonicerae, Radix Isatidis; Adjuvant drug Radix Platycodonis, Radix Glycyrrhizae;
Radix Helicteris, the micro-hardship of acrid in the mouth, cool in nature, there are relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, heat-clearing and toxic substances removing, reducing swelling and alleviating pain function.
Radix Picriae felterrae, bitter in the mouth, cold in nature, there are heat-clearing and toxic substances removing, reducing swelling and alleviating pain function.
Although this two tastes medicine of Radix Helicteris and Radix Picriae felterrae is all found that there is separately the effect to flu, has no the effect of two medicine compatibilities in prior art.
Inventor's discovery, the compatibility of two medicines, has synergism for heat-clearing and toxic substances removing, reducing swelling and alleviating pain.
Flos Lonicerae, bitter in the mouth, cold in nature, heat-clearing and toxic substances removing, and have the merit of light a surname's evacuation, be anemopyretic cold common medicine; Radix Isatidis, bitter in the mouth, cold in nature, heat-clearing and toxic substances removing, for affection due to external wind and heat, heating, laryngopharynx swelling and pain etc.Upper two medicines are strengthened monarch drug dispelling wind to relieve the exterior syndrome, heat-clearing toxin-expelling functions, are ministerial drug in side.
Radix Platycodonis, bitter in the mouth is pungent, and property is flat, opens lung qi dispersing gas, expelling phlegm for arresting cough; Radix Glycyrrhizae nourishing the lung to arrest cough, relieving spasm to stop pain, upper two medicines share lung qi dispersing eliminating phlegm and stopping cough, are adjuvant drug in side.
The raw material of Chinese medicine medicine pharmacological property of the above Chinese medicine composition:
1, Radix Helicteris is dry root or the Herb of Sterculiaceae plant Radix Helicteris Helicteres angustifolia L..Property hardship, cold.Function heat-clearing and toxic substances removing, for the high heat of catching a cold, tonsillitis, pharyngolaryngitis, parotitis, skin eczema.
2, Radix Picriae felterrae is the dry herb of goatweed Picria fel-terrae Lour..Property hardship, cold.Function heat-clearing and toxic substances removing, reducing swelling and alleviating pain.For cold anemopyretic, laryngopharynx swelling and pain, mumps, gastric heat stomachache, dysentery, furuncle and phyma, venom.
3, Flos Lonicerae is the dry flower of caprifoliaceae plant Radix Ophiopogonis Lonicera japonica Thunb. or the flower that band is just opened.Property sweet, cold.Function heat-clearing and toxic substances removing, wind-heat dissipating.For carbuncle furuncle, sore throat, erysipelas, toxic-heat and blood stasis, anemopyretic cold, pestilence heating.
4, the dry root of Baphicacanthus cusia root system cruciferae isatis Isatis indigotica Fort..Property hardship, cold.Function heat-clearing and toxic substances removing, removing heat from blood sore-throat relieving.For maculae caused by violent heat pathogen, crimson tongue is dark violet, mumps, sore throat, scarlet fever, major part pestilence, erysipelas, carbuncle.
5, Radix Platycodonis is the dry root of Campanulaceae Radix Platycodonis Platycodon grandiflorum (Jacq.) A.DC..Property hardship, pungent, flat.Function lung qi dispersing, sore-throat relieving, eliminate the phlegm, evacuation of pus.For cough with copious phlegm, uncomfortable in chest not smooth, pharyngalgia, hoarseness, lung abscess vomiting pus, skin infection difficulty in discharging of pus.
6, Radix Glycyrrhizae is the dry root and rhizome of glycyrrhizic legume Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L. Glycyrrhiza glabra L..Property sweet, flat.Function invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious pain of extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
The above raw material of Chinese medicine can mix with pharmaceutically acceptable adjuvant, makes various oral formulations, such as powder, capsule, tablet, electuary etc.
In one embodiment of the present invention, preparation method is:
1) prepare Flos Lonicerae volatile oil inclusion complex
Extract the method for volatile oil by routine and extract after Flos Lonicerae volatile oil, add inclusion material to be prepared into inclusion complex, the remaining Flos Lonicerae medicinal residues of institute give over to lower step and use.
2) other medical material is cut off respectively, pulverize, merge with Flos Lonicerae medicinal residues, decoct with water secondary, concentrated add ethanol and stir evenly, hold over night, filters, and reclaims ethanol, is concentrated into after thick paste, adds auxiliary materials and mixing, dry,
3) by 2) add 1 in gained medicated powder) the Flos Lonicerae volatile oil inclusion complex of gained;
4) add pharmaceutic adjuvant, after mix homogeneously, obtain powder.
Gained powder can be directly medicinal, also can make various preparations with it again.
In said method, described inclusion material comprises the cyclodextrin derivative such as alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin and 2,6 dimethyl-cyclodextrin.Described excipient substance comprises medicinal filler and lubricant, and wherein filler comprises starch, modified starch, dextrin, calcium hydrogen phosphate and other medicinal filler adjuvants, and lubricant comprises Polyethylene Glycol, calcium stearate, Pulvis Talci and other medicinal lubricants.
Advantage of the present invention and good effect:
This Chinese medicine composition is made according to theory of Chinese medical science and clinical practice experience, has good therapeutic effect for symptoms such as anemopyretic cold and the heating causing, cough and laryngopharynx swelling and pain.Carry out multinomial pharmacodynamic experiment with medicine of the present invention:
One, preclinical pharmacodynamics of San experiment
Show to have certain antibacterial, antitussive, diaphoresis, antipyretic, antiinflammatory, analgesia, immunoregulation effect, experimental result is as follows:
(1) In Vitro Bacteriostasis
Result shows, capsule of the present invention all has bacteriostasis in various degree to bacterial strains such as staphylococcus aureus (20771), staphylococcus aureus (18153), staphylococcus epidermidis (20289), α-hemolytic streptococcus (181818), streptococcus pneumoniae (B) 31002.
(2) mice is coughed to the impact of reaction
Result shows, medicine of the present invention can extend mouse cough incubation period to some extent, reduces mouse cough number of times.
(3) impact on normal rat sweat secretion
Result shows, normal rat paw portion sweat secretion is had to obvious facilitation.
(4) refrigeration function to rat
Result shows, to the exothermic reaction of 2,4-DNP pyrogenicity rat, all have inhibitory action in various degree.
(5) impact on mice ear
Result shows that Oleum Tiglii induced mice ear swelling is had to obvious inhibitory action.
(6) on the leukocytic impact in rat thoracic cavity
Result shows, can obviously suppress rat thoracic cavity leukoplania due to 1% carrageenin, but pleural effusion is not had to obvious inhibitory action.
(7) analgesic activity to mice
Result shows, can obviously suppress acetic acid induced mice writhing response, has obvious analgesic activity.
(8) impact on mouse immunity
Result shows, immunocompromised mice carbon powder is cleaned up to index K value remarkable increasing action, and the potentiation that this medicine has the immunity of immunocompromised mice is described.
But staphylococcus aureus infecting mouse is tested and is shown, medicine of the present invention does not have significant protective effect to staphylococcus aureus infecting mouse.Specific experiment data refer to embodiment.
Two, clinical pharmacodynamic experiment
Result shows, this traditional Chinese medicine composition for treating anemopyretic cold is rapid-action, and curative effect is high, safe and reliable, has good clinical efficacy, and anemopyretic cold total effective rate reaches 95.3%(and refers to embodiment).
The specific embodiment:
Below in conjunction with embodiment, the present invention is described in further detail, listed embodiment is only the present invention is described and is never limited to the present invention.
Embodiment 1 prevents and treats the Chinese medicine powder of anemopyretic cold
Raw material: Radix Helicteris 3.5kg, Radix Picriae felterrae 3.0kg, Flos Lonicerae 3.0kg, Radix Isatidis 3.0kg, Radix Platycodonis 1.0kg, Radix Glycyrrhizae 1.0kg
Preparation method:
1) prepare Flos Lonicerae volatile oil inclusion complex
A collects volatile oil
Adopt volatile oil catcher to carry out the collection of volatile oil, extracting honeysuckle 2.4kg, the 4-10 that adds water doubly measures, and each 3-5h, extracts 1 time, collects and obtains volatile oil 2ml, yield 0.083%.
B prepares beta-cyclo dextrin included compound
Volatile oil and beta-schardinger dextrin-are mixed and made into inclusion complex in 0.8-1.2:8 (ml/g) ratio: by beta-schardinger dextrin-8g add water 100ml make dissolve, measure volatile oil 0.8-1.2ml and a small amount of dehydrated alcohol dilution, under constantly stirring, be slowly added drop-wise in beta-schardinger dextrin-solution, in 45～50 ℃ of constant temperature, continue to stir after 3 hours, in 5～10 ℃, place 24 hours, filter, in 40 ℃ of cold drying, pulverize, sieve, obtain inclusion complex.
The inclusion complex of preparation is respectively according to two appendix XD of Chinese Pharmacopoeia version in 2005 as stated above, and in determination of volatile oil method mensuration inclusion complex, volatile oil content and inclusion complex recovery rate are calculated average inclusion 92.3%, and average recovery rate is 91.1%.Extract after volatile oil, the remaining Flos Lonicerae medicinal residues of institute give over to lower step and use.
2) other medical material is cut off respectively, pulverize, merge with Flos Lonicerae medicinal residues, decoct with water secondary, amount of water is 5～12 times of medical material amount for the first time, soaks 0.5～1h, heated and boiled 1～3h; Amount of water is 5～12 times of medical material amount for the second time, boils 1～3h; Filter, merging filtrate, is concentrated into the clear paste that density is 1.10～1.20g/ml, add ethanol, reach 50～90%(percent by volume to ethanol content in total amount) time, stir evenly, hold over night, filter, decompression heating recovery ethanol, is concentrated into thick paste, add starch 0～1.5kg, mix, dry, pulverize and sieve 80～100 orders;
3) by 2) add 1 in gained medicated powder) the Flos Lonicerae volatile oil inclusion complex of gained;
4) add modified starch 0～1.5kg, after mix homogeneously, obtain powder.
The Chinese medicine powder of embodiment 2～4 preventions and treatment anemopyretic cold
Preparation method is with embodiment 1, and only material composition is different with consumption.
Embodiment 5 prevents and treats the Chinese medicine capsules of anemopyretic cold
Ingredient and consumption be with embodiment 1, in preparation method, 1), 2), 3) step is with embodiment 1;
Step 4) adds starch and the each 0～1.5kg of Pulvis Talci, encapsulated and get final product every capsules 5g after mix homogeneously.
The Chinese medicine capsules of embodiment 6～8 preventions and treatment anemopyretic cold
Preparation method is with embodiment 5, and only material composition is different with consumption.
Embodiment 9 prevents and treats the Chinese medicinal tablet of anemopyretic cold
Ingredient and consumption be with embodiment 1, in preparation method, 1), 2), 3) step is with embodiment 1;
Step 4): add starch 0～1.5kg, after mix homogeneously, granulate, dry, tablet machine film-making, every weight is 0.5g.
The Chinese medicinal tablet of embodiment 10～11 preventions and treatment anemopyretic cold
Preparation method is with embodiment 9, and only material composition is different with consumption.
The amount ratio of each embodiment Raw is in table 1
The amount ratio of the each embodiment Raw of table 1.
Preclinical pharmacodynamics of San experiment
(1) In Vitro Bacteriostasis
Adopt plate doubling dilution, the Experimental agents having diluted (capsule of embodiment 5-8) is added respectively in the sterilising medium that is cooled to 55 ℃ of left and right, mix, make the medicine flat board of variable concentrations.Experimental bacteria suspension (the bacterial concentrations 10 such as depletion Staphylococcus aureus, α-hemolytic streptococcus, streptococcus pneumoniae
5cFU/ml), draw respectively and plant in the pastille flat board of variable concentrations, cultivate 18h, observed and recorded minimal inhibitory concentration (MIC) for 37 ℃.
The results are shown in Table 2.
Table 2. In Vitro Bacteriostasis
Result shows, capsule of the present invention all has bacteriostasis in various degree to trial bacterial strain.
Below in experiment, Experimental agents used is embodiment 6 capsules.
(2) mice ammonia mist is caused to the impact of coughing reaction
50 of mices, female, hero half and half, body weight 20 ± 2g, is divided into 5 groups at random, 10 every group.Wherein organize ig respectively and give capsule of the present invention 6.0,3.0,1.5/kg for 3; 1 group ig gives intensified loquet capsule 3.0/kg; Yu 1 group be blank group, give equivalent distilled water.Be administered once every day, 3d continuously, and 1h after last medicine, every Mus constant-pressure atomization ammonia 15s, observes the incubation period of mouse cough, and records mouse cough number of times in 2min.The results are shown in Table 3.
Table 3. capsule of the present invention causes on mice ammonia mist the impact of coughing reaction
T check, with relatively * P<0.05**P<0.01***PLEssT.LTssT. LT0.001 of matched group
Result shows, 6.0,3.0,1.5/kg of capsule of the present invention all has and extends to some extent mouse cough incubation period, reduces mouse cough number of times.
(3) impact on normal rat paw sweat secretion (colouring)
Get 50 of rats, male and female half and half, body weight 160 ± 40g, is divided into 5 groups at random, 10 every group.Wherein organize ig respectively and give capsule of the present invention 6.0,3.0,1.5/kg for 3; 1 group ig gives Ephedrae Decoction 1g/kg; Yu 1 group be blank, ig is to equal-volume distilled water.After administration, rat is inserted respectively in rat fixator, face upward position fixing, expose two hind legs, dip dehydrated alcohol gently by sufficient sole of the foot portion dirt scrub with cotton swab, then wipe gently dry with dry cotton swab, after administration, 15min coats and field-Gao Yuan Shi reagent A liquid in rat paw portion skin, after fully dry, the very thin B liquid of coating of 30min after administration, observes and records the Chinese and count after 30min, 1 integral and calculating pressed in a Chinese, the difference of comparative control group and medicine group.The results are shown in Table 4.
The impact of table 4. capsule of the present invention on normal rat paw sweat secretion
T check, with relatively * * P<0.01 of matched group
Result shows, 6.0,3.0,1.5/kg of capsule of the present invention all has obvious facilitation to normal rat paw portion sweat secretion.
(4) refrigeration function to 2,4-DNP pyrogenicity rat
Rat body weight 250 ± 40g, female, male half and half, before experiment, water 16h is can't help in fasting, and the same day was measured rat temperature 2 times in experiment, chose body temperature and changed 50 of rats that are no more than 0.3 ℃, was divided into 4 groups, 10 every group.Wherein organize ig respectively and give capsule of the present invention 6.0,3.0,1.5/kg for 3; 1 group of ig is to aspirin 0.3g/kg; Yu 1 group be blank, ig is to equivalent distilled water.30min subcutaneous accurate injection 2 in each Mus back after medicine, 2, 4-dinitrophenol solution 20mg/kg, after pyrogenicity, each group of 45min is administered once again, after pyrogenicity respectively at 0.5,1,2,3,4,5h measures rat temperature 1 time, survey altogether 6 times, calculate each group of rat temperature changing value.The results are shown in Table 5.
The refrigeration function of table 5. capsule of the present invention to 2,4-DNP pyrogenicity rat
T check, with relatively * P<0.05**P<0.01***PLEssT.LTssT. LT0.001 of matched group
Result shows, the exothermic reaction of 6.0,3.0,1.5/kg of capsule of the present invention to 2,4-DNP pyrogenicity rat, all has inhibitory action in various degree.
(5) impact on Oleum Tiglii induced mice ear swelling
50 of mices, female, hero half and half, body weight 20 ± 2g, is divided into 5 groups at random, 10 every group.Wherein organize ig respectively and give capsule of the present invention 6.0,3.0,1.5/kg for 3; 1 group ig gives dexamethasone tablet 2.5/kg; Yu 1 group be blank, ig is to equivalent distilled water.30min after medicine, the left ear of each Mus causes inflammation with 2% Oleum Tiglii mixture 0.05ml/ ear, and auris dextra compares.Cause scorching rear 30min and be administered once again, after 4h, mice is broken to cervical vertebra and put to death, cut two ears, lay garden auricle at coating position respectively with diameter 9mm card punch, take mice left and right ear weight with analytical balance, using its difference as inflammatory swelling degree, and calculate swelling inhibition percentage.The results are shown in Table 6.
The impact of table 6. capsule of the present invention on the swelling of Oleum Tiglii induced mice auricular concha
T check, with relatively * * * P<0.001*P<0.05 of matched group
Result shows, 6.0/kg of capsule of the present invention has obvious inhibitory action to Oleum Tiglii induced mice ear swelling.
(6) impact on rat thoracic cavity leukoplania
Get 50 of rats, male and female half and half, body weight 210～240g, is divided into 5 groups by body weight, 10 every group.Wherein 3 groups of ig give capsule of the present invention 6.0,3.0,1.5/kg; 1 group of positive matched group, ig gives dexamethasone tablet 2.5/kg, remaining 1 group be blank group, ig waits capacity distilled water.Administration every day 1 time, 10d continuously, 1h after last administration only causes inflammation from right side intrapleural injection 1% carrageenin 0.2ml/ under ether light anaesthesia, puts to death rat after 5h, opens thoracic cavity, with suction pipe sucking-off pleural effusion, records transudate volume and counts total white blood cells.The results are shown in Table 7.
The impact of table 7. capsule of the present invention on rat thoracic cavity leukoplania
T check, with relatively * P<0.05**P<0.01 of matched group
Result shows, 6.0,3.0,1.5/kg of capsule of the present invention all can obviously suppress rat thoracic cavity leukoplania due to 1% carrageenin, but pleural effusion is not had to obvious inhibitory action.
(7) impact of Dichlorodiphenyl Acetate induced mice writhing response
50 of mices, female, hero half and half, body weight 20 ± 2g, is divided into 5 groups at random, 10 every group.Wherein organize ig respectively and give capsule of the present invention 6.0,3.0,1.5/kg for 3; 1 group ig gives aspirin 0.3g/kg; Yu 1 group be blank, ig is to equivalent distilled water.30min after administration, each Mus respectively lumbar injection 0.6% glacial acetic acid 0.2ml/ only, is observed the writhing response number of times occurring in the rear 20min of injection.The results are shown in Table 8.
The impact of table 8. capsule Dichlorodiphenyl Acetate of the present invention induced mice writhing response
T check, with relatively * P<0.05**P<0.01***PLEssT.LTssT. LT0.001 of matched group
Result shows, 6.0,3.0,1.5/kg of capsule of the present invention all can obviously suppress acetic acid induced mice writhing response, has obvious analgesic activity.
(8) on impact that in immunocompromised Mice Body, carbon granule is cleaned up function
Get 60 of mices, male and female half and half, body weight 18～22g, is evenly divided into 6 groups by body weight, 10 every group.Wherein 3 groups of ig give capsule of the present invention 6.0,3.0,1.5/kg; 2 groups is blank group and model group, and ig waits capacity distilled water; Yu 1 group of positive matched group, ig gives SHENQI PIAN 0.75g/kg.Administration every day 1 time, successive administration 7d.In 6d ig administration simultaneously, except blank group, all the other 5 groups of mices respectively subcutaneous injection prednisolone acetate 25mg/kg are made immunodeficiency models, after 24h (not 1h after time administration), the india ink 0.1ml/10g body weight of mouse tail vein injection 10%, 2min and the 7min eye socket venous plexus 20 μ l that take a blood sample after injection, be dissolved in 2ml0.1%Na2CO3 solution, put 722 type spectrophotometers and measure trap in 680nm place, and cut open and get liver, spleen and weigh and calculate its organ coefficient, calculate that carbon powder is cleaned up index K and index α is cleaned up in correction.The results are shown in Table 9.
Table 9. capsule of the present invention is cleaned up the impact of ability on mice carbon granule
T check, with matched group comparison
Δ Δp<0.01
Δ Δ Δp<0.001; Compare * P<0.05 with prednisolone acetate (model group)
Result shows, 6.0,3.0,1.5/kg of capsule of the present invention cleans up index K value to immunocompromised mice carbon powder remarkable increasing action, and the potentiation that this medicine has the immunity of immunocompromised mice is described.
(9) protective effect of mouse experiment antibacterial being infected
80 of mices, female, hero half and half, body weight 20 ± 2g, is divided into 4 groups at random, 20 every group.Wherein organize oral cavity respectively and give capsule of the present invention 21.6,5.4/kg for 2; 1 group ig gives acetyl Luo Xuan mycin 1g/kg; Yu 1 group be blank, ig is to equal-volume distilled water.Be administered once every day, continuously 3d.Staphylococcus aureus is inoculated in 2ml nutrient broth, cultivate 8h for 37 ℃, get 0.1ml transferred species in 10ml nutrient broth, cultivate 18h for 37 ℃, for experiment original bacteria liquid, original bacteria liquid is suitably diluted with physiological saline solution, be finally diluted to infection animal 100% minimum lethal dose (MLD) with 5% high activity dried yeast liquid.1h after last medicine, the bacteria suspension 0.5ml of definite MLD (1 × 105CFU/ml) in every mouse peritoneal of injection prerun, 2h administration 1 time again after microbiological contamination, Continuous Observation 7d, records each group of dead mouse situation.The results are shown in Table 10.
The vivo bacteria corrosion action of table 10. capsule of the present invention to staphylococcus aureus infecting mouse
X
2check, with matched group comparison, * * P<0.01
Result shows, 21.6,5.4/kg of capsule of the present invention does not have significant protective effect to staphylococcus aureus infecting mouse.
Clinical pharmacodynamic experiment
(1) case selection standard:
Disease is shown in heating micro evil wind, and antiperspirant is let out not smooth, distending pain in the head, and cough, expectorant is sticky or yellow, parched throat, laryngopharynx swelling and pain, nasal obstruction, stream turbid nasal discharge, thirst with desire to drink, tongue tip side of red, thin lingual fur or micro-Huang, floating and rapid pulse person.
(2) Therapeutic Method:
Embodiment 1 medicated powder for oral administration, 3 times on the one 7th is a course for the treatment of, after the course for the treatment of, optionally appends treatment.Viewing duration requires the medicine without other treatment primary disease.
(3) effect criterion:
1, effective: anemopyretic cold relevant symptoms disappears, sign and lab testing are without extremely.
2, take a turn for the better: anemopyretic cold relevant symptoms, sign and lab testing are improved.
3, invalid: anemopyretic cold relevant symptoms, sign and lab testing are all without improving.
(4) result:
My Out-patient Department portion treats total case load 85 people altogether, wherein: effective 75 people, take a turn for the better 6 people, invalid 4 people, total effective rate 95.3%.Above results suggest this Chinese medicine composition anemopyretic cold is had to good clinical efficacy.
(5) model case:
Case 1
Revive certain, man, 7 years old.In February, 2002, main suit was because upper sense causes heating 4d, used quiet of penicillin, and after each transfusion, body temperature can be down to normally, cross body temperature after 2～3h and start again to raise, with afternoon, night for very, 38.5 ℃～40.0 ℃ of body temperature, nasal obstruction, watery nasal discharge, cough, pharyngalgia, red tongue, yellow fur, floating and tense pulse.Lab testing: leukocyte 11.0 × l0
9/ L, neutrophilic granulocyte 0.72%.Chest X-rays: two lung marking strengthen.Give the Drug therapy in the present embodiment 1, after medication 2d, heating stops, and after 5d, fully recovers.
Song, man, 27 years old, in June, 2002 recurrent cough of main suit 5d, heating 2d, once Oral Acetyl Spiramycin sheet 2d treatment, symptom is without improvement.39.6 ℃ of body temperature, pharyngeal congestion, antiadoncus, leukocyte 13.0 × 10
9/ L, neutrophilic granulocyte 0.82%.Give the Drug therapy in the present embodiment 1, after medication 1d, heating stops, and after 7d, fully recovers.
Huang, female, 25 years old, 3d was medical on August 30th, 2003 for patient's heating, cough companion malaise.There is heating, cough in main suit's 3d cause, has a little mucoid expectorant after suffering from cold, headache, and pharyngalgia discomfort, general fatigue is unable, and loss of appetite is felt sick.After private clinic treatment, (use the medicines such as KUAIKE, cefradine, SHUANGHUANLIAN, ampicillin).The state of an illness still increases the weight of gradually.Have a medical check-up: 38.5 ℃ of body temperature.110 beats/min, pulse.Breathe 21 beats/min.Sanity, listlessness.Swallow red.Two pulmonary respiration sounds are low, audible and dry moist rale.Leukocyte 15.0 × 10
9/ L, neutrophilic granulocyte 0.86%.Rabat shows bottom right pulmonary infection.Give the Drug therapy in the present embodiment 1, after medication 3d, heating stops, and after 12d, fully recovers.
Claims (10)
1. the application of the effective ingredient of Radix Helicteris and Radix Picriae felterrae composition in the medicine of preparation prevention and treatment anemopyretic cold, the weight portion proportioning of two survival doses is 6～8 parts of Radix Helicteriss, 5～7 parts of Radix Picriae felterrae.
2. application according to claim 1, prepares in the raw material of described medicine and also comprises 5～7 parts of Radix Isatidis and/or the volatile oil made from 5～7 portions of Flos Loniceraes.
3. application according to claim 1 and 2, prepares in the raw material of described medicine and also comprises Radix Platycodonis and/or Radix Glycyrrhizae, and consumption is 1.6～2.4 parts of Radix Platycodoniss, 1.6～2.4 parts, Radix Glycyrrhizae.
4. application according to claim 3, the weight ratio of preparing the raw material of described medicine is: 2 parts, 7 parts of Radix Helicteriss, 7 parts of Radix Picriae felterrae, 6 parts of Flos Loniceraes, 6 parts of Radix Isatidis, 2 parts of Radix Platycodoniss and Radix Glycyrrhizae; Described Flos Lonicerae is that Flos Lonicerae volatile oil inclusion complex and Flos Lonicerae are extracted the medicinal residues after volatile oil.
5. a medicine for prevention and treatment anemopyretic cold, is characterized in that containing Radix Helicteris and Radix Picriae felterrae, and the weight portion proportioning of two survival doses is 6～8 parts of Radix Helicteriss, 5～7 parts of Radix Picriae felterrae.
6. medicine according to claim 5, prepares in the raw material of described medicine and also comprises 5～7 parts of Radix Isatidis and/or the volatile oil made from 5～7 portions of Flos Loniceraes.
7. according to the medicine described in claim 5 or 6, to prepare in the raw material of described medicine and also comprise Radix Platycodonis and/or Radix Glycyrrhizae, consumption is 1.6～2.4 parts of Radix Platycodoniss, 1.6～2.4 parts, Radix Glycyrrhizae.
8. according to the medicine described in claim 6 or 7, described volatile oil is Flos Lonicerae volatile oil inclusion complex, and in described raw material, also comprises the medicinal residues after Flos Lonicerae extraction volatile oil.
9. medicine according to claim 8, the inclusion material of described Flos Lonicerae volatile oil inclusion complex is selected from alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin or 2,6 dimethyl-cyclodextrin.
10. according to arbitrary described medicine in claim 5～9, be oral agents, be selected from powder, capsule, tablet or electuary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410082674.0A CN103816281B (en) | 2013-12-24 | 2014-03-07 | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310731421 | 2013-12-24 | ||
| CN2013107314217 | 2013-12-24 | ||
| CN201310731421.7 | 2013-12-24 | ||
| CN201410082674.0A CN103816281B (en) | 2013-12-24 | 2014-03-07 | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103816281A true CN103816281A (en) | 2014-05-28 |
| CN103816281B CN103816281B (en) | 2016-06-29 |
Family
ID=50751762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410082674.0A Active CN103816281B (en) | 2013-12-24 | 2014-03-07 | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103816281B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560554A (en) * | 2016-02-23 | 2016-05-11 | 广西梧州制药（集团）股份有限公司 | Traditional Chinese medicine composition for diminishing inflammation and relieving sore throat and preparation method thereof |
| CN107050087A (en) * | 2017-03-24 | 2017-08-18 | 华润三九（郴州）制药有限公司 | It is a kind of to treat medicine of anemopyretic cold and its preparation method and application |
| CN108404140A (en) * | 2016-06-01 | 2018-08-17 | 湖南安邦制药有限公司 | A kind of clathrate process of volatile oil |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823902A (en) * | 2005-12-23 | 2006-08-30 | 桂林三金药业股份有限公司 | Chinese medicinal composistion for treating common cold, its preparation method and quality control method |
| CN101023764A (en) * | 2006-02-20 | 2007-08-29 | 耿军 | Chrysanthemum epidermic-prevention pharynt-clearing tea and preparing method |
| CN101181393A (en) * | 2007-11-22 | 2008-05-21 | 张树球 | Chinese medicine preparation for curing common cold and producing method thereof |
| CN101690745A (en) * | 2009-10-30 | 2010-04-07 | 福州市仓山区金点子信息咨询有限公司 | Chinese medicinal composition for preventing and treating flu |
| CN102114197A (en) * | 2010-05-13 | 2011-07-06 | 于进香 | Traditional Chinese medicine oral decoction for treating influenza |
| CN102397338A (en) * | 2010-09-16 | 2012-04-04 | 上海玉森新药开发有限公司 | Chinese medicine composition for treating influenza |
| CN103341086A (en) * | 2013-07-16 | 2013-10-09 | 冯宇伟 | Medicine for preventing and treating influenza and preparation method thereof |
-
2014
- 2014-03-07 CN CN201410082674.0A patent/CN103816281B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823902A (en) * | 2005-12-23 | 2006-08-30 | 桂林三金药业股份有限公司 | Chinese medicinal composistion for treating common cold, its preparation method and quality control method |
| CN101023764A (en) * | 2006-02-20 | 2007-08-29 | 耿军 | Chrysanthemum epidermic-prevention pharynt-clearing tea and preparing method |
| CN101181393A (en) * | 2007-11-22 | 2008-05-21 | 张树球 | Chinese medicine preparation for curing common cold and producing method thereof |
| CN101690745A (en) * | 2009-10-30 | 2010-04-07 | 福州市仓山区金点子信息咨询有限公司 | Chinese medicinal composition for preventing and treating flu |
| CN102114197A (en) * | 2010-05-13 | 2011-07-06 | 于进香 | Traditional Chinese medicine oral decoction for treating influenza |
| CN102397338A (en) * | 2010-09-16 | 2012-04-04 | 上海玉森新药开发有限公司 | Chinese medicine composition for treating influenza |
| CN103341086A (en) * | 2013-07-16 | 2013-10-09 | 冯宇伟 | Medicine for preventing and treating influenza and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 董青松等: "苦玄参研究概况", 《大众科技》, vol. 15, no. 3, 31 December 2013 (2013-12-31), pages 92 - 94 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560554A (en) * | 2016-02-23 | 2016-05-11 | 广西梧州制药（集团）股份有限公司 | Traditional Chinese medicine composition for diminishing inflammation and relieving sore throat and preparation method thereof |
| CN108404140A (en) * | 2016-06-01 | 2018-08-17 | 湖南安邦制药有限公司 | A kind of clathrate process of volatile oil |
| CN107050087A (en) * | 2017-03-24 | 2017-08-18 | 华润三九（郴州）制药有限公司 | It is a kind of to treat medicine of anemopyretic cold and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103816281B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105560372A (en) | Traditional Chinese medicine spray for treating rhinitis and preparation method thereof | |
| CN105616590A (en) | Composition capable of clearing heat from throat, and preparation method thereof | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN103768308A (en) | Medicament composition for treating upper respiratory infections and preparation method thereof | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN114073730A (en) | Traditional Chinese medicine composition for preventing or treating air-conditioning syndrome | |
| CN101628108B (en) | Traditional Chinese medicinal granules for treating wind-cold evil and preparation method thereof | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN103816281B (en) | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold | |
| CN101618146A (en) | Complex traditional Chinese medicine preparation for treating upper respiratory tract infection and preparation method thereof | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN105381310A (en) | Traditional Chinese medicine preparation for treating phthisis and preparing method thereof | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN104383318A (en) | Chinese traditional medicine composition for treating tuberculosis and preparation method of Chinese traditional medicine composition | |
| CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
| CN100563677C (en) | A kind of moistening and cleaning throat Chinese medicine preparation | |
| CN105853566A (en) | Medicinal composition for treating acute tonsillitis, acute pharyngitis and acute laryngitis | |
| CN101804149B (en) | Traditional Chinese medicine for treating faucitis | |
| CN103977226A (en) | Traditional Chinese medicine compound preparation for treating pediatric cold and preparation method thereof | |
| CN104524256A (en) | Traditional Chinese medicine for treating viral pneumonia | |
| CN101810675A (en) | Medicament for treating pharyngitis | |
| CN103463444B (en) | Traditional Chinese medicine composition for treating phlegm stagnation cross-resistance type acnes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Song Zhizhao Inventor after: Zhang Ying Inventor after: Liang Wei Inventor after: Ma Zhonglin Inventor after: Liu Yuan Inventor after: Wen Zhiyun Inventor after: Li Xingyu Inventor after: Lantaijin Inventor before: Lantaijin Inventor before: Liu Yuan Inventor before: Zhang Ying Inventor before: Song Zhizhao Inventor before: Wen Zhiyun Inventor before: Li Xingyu |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LAN TAIJIN LIU YUAN ZHANG YING SONG ZHIZHAO WEN ZHIYUN LI XINGYU TO: SONG ZHIZHAO ZHANG YING LIANG WEI MA ZHONGLIN LIU YUAN WEN ZHIYUN LI XINGYU LAN TAIJIN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140528 Assignee: GUANGXI WUZHOU SANHE PHARMACEUTICAL CO.,LTD. Assignor: GUANGXI INSTITUTE OF CHINESE MEDICINE & PHARMACEUTICAL SCIENCE Contract record no.: X2023980044815 Denomination of invention: A Traditional Chinese Medicine Composition for Preventing and Treating Wind Heat and Cold Granted publication date: 20160629 License type: Common License Record date: 20231031 |
|
| EE01 | Entry into force of recordation of patent licensing contract |